C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Danny Rischin, Daniel Brungs, Fiona Day, Hayden Robert Christie, Vishal A. Patel, Gerard Adams, James Estes Jackson, Maite De Liz Vassen Schurmann, Dmitry Kirtbaya, Thuzar M. Shin, Christopher David Hart, Elizabeth Stankevich, Siyu Li, Israel Lowy, Hyunsil Han, Matthew G. Fury, Sandro Porceddu
Institutions: Peter MacCallum Cancer Centre, Wollongong Hospital, Calvary Mater Newcastle Hospital, George Washington University, Universidade do Planalto Catarinense, Oncological Dispensary No. 2, Hospital of the University of Pennsylvania, St Vincent's Hospital Melbourne, Regeneron (United States), The University of Queensland
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286294916